Novel mechanism offers hope for improved tolerability and efficacy in patients facing resistance or long-term toxicity with existing TKIs.
Amber Clemmon, PharmD, BCOP, FHOPA
Advertisement
Articles by Amber Clemmon, PharmD, BCOP, FHOPA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Nipah Outbreak in India Poses Low Global Risk Despite Lack of Approved Treatments
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
5